Endometrial Cancer | Clinical

Pembrolizumab and Lenvatinib Approval Opens New Door in Endometrial Cancer Treatment

October 12, 2022

Wesley Burkett, MD, adiscusses his excitement for the approval of pembrolizumab in combination with lenvatinib for patients with advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient.

Recurrent Metastatic EC: Common Immune-Related Adverse Events And Patient Discussions

September 26, 2022

Bhavana Pothuri, MD provides a perspective on the management of immune-related adverse events that can be seen in patients treated for recurrent metastatic endometrial cancer, as well as a focused discussion on the conversations she has with her patients.